Charles River has been riding rough waters in 2024, and as the CRO’s CEO predicted, the third quarter proved no exception. | ...

When tested in mice, the compound—named BBI-2779—shrank gastric tumors and prevented the cancer from developing resistance to ...

The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which the agency described as ...

Ring Therapeutics is calling on Singaporean research agencies to dial into a new collaboration to develop gene therapies for eye diseases and cancer. | Ring Therapeutics is calling on Singaporean ...

Acadia Pharmaceuticals has bagged $150 million from the sale of a priority review voucher (PRV)—although the biotech will ...

Tumors outside the central nervous system (CNS) did respond but the failure to shrink brain tumors took away TNG908’s raison d'etre. Tango has another MTA-cooperative PRMT5 inhibitor, TNG462, for ...

MacroGenics has pumped the brakes on vobramitamab duocarmazine (vobra duo), pausing investment in additional opportunities ...

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 ...

Medtronic and Recor Medical may have some fresh resolutions for the new year after the Centers for Medicare & Medicaid ...

Medidata has debuted two new bundled services meant to speed up and support clinical trials in oncology and vaccines, the ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

A 2016 survey by the journal Nature put stark numbers to the scope of science’s reproducibility problems. | A 2016 survey by the journal Nature put stark numbers to the scope of science’s ...